Home / Health / New Ebola Vaccines Enter Critical Trials in DRC

New Ebola Vaccines Enter Critical Trials in DRC

Summary

  • Two new Ebola vaccine candidates are now in clinical trials.
  • Vaccines target the Bundibugyo virus causing the current outbreak.
  • Trial results are expected in early 2027.

Two promising Ebola vaccine candidates have been recommended for inclusion in ongoing clinical trials in the Democratic Republic of the Congo (DRC). The vaccines, developed by the University of Oxford with the Serum Institute of India and by Moderna, are the first to be specifically evaluated against the Bundibugyo virus during an active outbreak. The WHO's Technical Advisory Group on Candidate Vaccine Prioritization made the recommendation based on preclinical and early clinical evidence. These candidates will enter the Tumaini trial, which uses a ring-vaccination approach involving contacts of confirmed cases. This approach builds on successful methods used in past Ebola outbreaks.

Beyond vaccines, research into treatments is also progressing. A trial launched in July is assessing monoclonal antibodies and antivirals for confirmed Bundibugyo virus disease. Complementary studies on post-exposure prophylaxis are also underway. The WHO is providing significant support for this research, integrating rigorous ethical studies into the ongoing response. Initial findings from the treatment trials are expected in the coming months, while the results from the vaccine trial are anticipated in early 2027, offering a potential new tool to control the outbreak.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571